ArticleBMJ open2023
Implementation of a culturally competent
Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrating a Culturally Competent APOL1 Genetic Testing Program Into Living Donor Evaluation
APOL1 Genetic Testing Program for Living Donors, Part 2
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Apolipoprotein L1 Genetic Testing and Counseling Does Not Reduce Living Kidney Donors' Willingness to Donate : A Hybrid Type 2 Nonrandomized Controlled Trial.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Non-HLA Genetics and Application to Living Donor Candidates.Current transplantation reports · 2025Article
- Development and Evaluation of a Culturally TargetedKidney medicine · 2025Article
- Review
- Contextual factors of implementing APOL1 genetic testing into living kidney donor clinical evaluation.Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025Article
- Advancing Genetic Testing in Kidney Diseases: Report From a National Kidney Foundation Working Group.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024Review
- Attitudes Toward Use of an APOL1 Genetic Testing Chatbot in Living Kidney Donor Evaluation: A Focus Group Study.Clinical transplantation · 2024Article
- Strategies for choosing the best living donor: A review of the literature and a proposal of a decision-making paradigm.Pediatric transplantation · 2024Review
- Development of a culturally targeted chatbot to inform living kidney donor candidates of African ancestry about APOL1 genetic testing: a mixed methods study.Journal of community genetics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
Abstract
introductionWhile living donor (LD) kidney transplantation is the optimal treatment for patients with kidney failure, LDs assume a higher risk of future kidney failure themselves. LDs of African ancestry have an even greater risk of kidney failure post-donation than White LDs. Because evidence suggests that Apolipoprotein L1 ( METHODS AND ANALYSIS: Using a non-randomised, pre-post trial design in two transplant centres (Chicago, IL, and Washington, DC), we will evaluate the effectiveness of culturally competent ETHICS AND DISSEMINATION: This study will create a model for
trial registrationClinicalTrials.gov Identifier: NCT04910867. Registered 8 May 2021, https://register. CLINICALTRIALS: gov/prs/app/action/SelectProtocol?sid=S000AWZ6&selectaction=Edit&uid=U0001PPF&ts=7&cx=-8jv7m2 ClinicalTrials.gov Identifier: NCT04999436. Registered 5 November 2021, https://register. CLINICALTRIALS: gov/prs/app/action/SelectProtocol?sid=S000AYWW&selectaction=Edit&uid=U0001PPF&ts=11&cx=9tny7v.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.